Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Biome Australia's Debt-to-EBITDA or its related term are showing as below:
ASX:BIO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.01 Med: -0.26 Max: 4.78
Current: 1.69
During the past 5 years, the highest Debt-to-EBITDA Ratio of Biome Australia was 4.78. The lowest was -1.01. And the median was -0.26.
ASX:BIO's Debt-to-EBITDA is ranked better than 55.41% of 1554
companies
in the Consumer Packaged Goods industry
Industry Median: 2.12
vs ASX:BIO: 1.69
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Biome Australia Debt-to-EBITDA Related Terms
Biome Australia Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Biome Australia's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Biome Australia's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biome Australia Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Biome Australia's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biome Australia's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Biome Australia (ASX:BIO) has a Debt-to-EBITDA of 0.85 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Biome Australia. According to the industry distribution chart, Biome Australia ranks #693 out of 1554 companies in the Consumer Packaged Goods industry, placing it in the top 44.6%.
Is Biome Australia's Debt-to-EBITDA too high?
Biome Australia's current Debt-to-EBITDA is 0.85. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.12. Biome Australia's value of 0.85 is 59.9% below this industry median. Based on the distribution chart, Biome Australia ranks #693 out of 1554 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Biome Australia has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biome Australia's Debt-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Biome Australia ranks #693 out of 1554 companies for Debt-to-EBITDA. This puts Biome Australia in the upper half of its industry. The industry median Debt-to-EBITDA is 2.12. Biome Australia's value of 0.85 is 59.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.12, based on 1,554 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biome Australia's current Debt-to-EBITDA of 0.85 is 59.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Biome Australia. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biome Australia's current Debt-to-EBITDA is 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biome Australia stock overvalued right now?
Based on GuruFocus' analysis, Biome Australia (ASX:BIO) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.68, compared to a current price of A$0.30 — trading 56.6% below its estimated fair value. The current Debt-to-EBITDA is 0.85 and 59.9% below the Consumer Packaged Goods industry median of 2.12. Biome Australia's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Biome Australia (ASX:BIO), the current Debt-to-EBITDA is 0.85 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biome Australia (ASX:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biome Australia stock appears to be undervalued.
The current stock price of A$0.30 is trading 56.6% below its estimated GF Value™ of A$0.68.
GuruFocus considers Biome Australia to be Possible Value Trap.
Key valuation signals for ASX:BIO:
Debt-to-EBITDA: 0.85
GF Value™: A$0.68 vs. price of A$0.30 (56.6% below fair value)
Industry Position: 59.9% below the Consumer Packaged Goods median (#693 of 1554)
No single metric tells the full story. See the ASX:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biome Australia Ltd licences, develops, and markets evidence-based, complementary medicines, including nutraceuticals vitamins and weight management products and live biotherapeutics. The company has one operating segment: researching, developing, manufacturing and distributing evidence-based products linking the gut and human health. Domestically it caters to Australia and In international markets, the Group distributes and markets its Activated Probiotics range in the United Kingdom and New Zealand through independent health practitioners.
31GF Score
Get the complete analysis for ASX:BIO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BIO has been successfully added to your 
